The Right Trials, Patients, and Places for Meaningful Oncology Research
Innovative research requires an ingenious mediation of patient and program needs. Worldwide excels in the essentials while taking a vanguard approach to the latest in preclinical science and study design.
TEAM BACKGROUND MAKES A DIFFERENCE
Many of our oncology team members have spent time conducting research or clinical care themselves, giving them an edge in overcoming the operational and patient-centered challenges that often plague trials conducted in this space. From preclinical and dose escalation expertise to regulatory approval, we are just the right size to offer accessible, nimble attention and a bevy of the industry’s top talent. That’s why Worldwide is rated a top performer for staff, delivery, budget and loyalty across phase I-III CRO services by Industry Standard Research.
CLARE WALLIS
PRESIDENT OF ONCOLOGY BUSINESS UNIT
Clare has held responsibilities at all levels of drug development including data manager, clinical research associate, global project management lead, and more. Clare’s experience is invaluable in guiding and supporting operational teams in achieving project success. From project planning, execution, oversight, to patient recruitment, team mentoring, and sponsor engagement, Clare is well-versed in mitigating risks and creating a culture of effective communication among stakeholders and team members for optimal results.
GARY FISHBEIN
VICE PRESIDENT, THERAPEUTIC AREA LEAD, ONCOLOGY
Gary Fishbein, MD, MPH, Vice President, Therapeutic Area Lead, Oncology has more than two decades of experience in oncology drug development within biotech, pharma, and CRO. He is a board-certified oncologist with experience across all phase of development in various tumor types such as breast cancer, Hodgkin and non-Hodgkin lymphomas, cutaneous T-cell lymphoma, head and neck cancer, non-small cell lung cancer, prostate cancer, adult leukemia, gastrointestinal cancers, renal cell cancer, gynecologic malignancies, giant cell tumor of tendon sheath, multiple myeloma, and glioblastoma multiforme, to name a few.
He engages with staff to ensure successful integration of feasibility assessments, trial designs, clinical operations, and regulatory processes. A member of the American Society of Clinical Oncology, he has lectured, authored, and co-authored on such indications as T-cell lymphoma, adolescent melanoma, pancreatic cancer, metastatic breast cancer, systemic amyloidosis, acute myeloid leukemia, Hodgkin lymphoma, and hepatocellular carcinoma.
DANA F. DURST
SENIOR DIRECTOR, SITE ACTIVATION & REGULATORY THERAPEUTIC LEAD, ONCOLOGY
Dana F. Durst, Senior Director, Site Activation & Regulatory Therapeutic Lead, Oncology, at Worldwide Clinical Trials has more than 16 years of clinical research experience. Her experience ranges among a broad span of therapeutic areas including oncology, gene therapy, NASH, dermatology, ophthalmology, and cardiovascular studies extending from Phase I-IV. She has overseen all aspects of startup as well as maintenance activities in a variety of countries worldwide in both early and late phase trials, and with both small, agile clients and large clients.
LEANNE DRUMMOND
SENIOR DIRECTOR, PROJECT MANAGEMENT, ONCOLOGY AND RARE DISEASES
Leanne has more than 25 years of project management experience in CROs and the pharmaceutical industry, specializing in oncology studies. She is skilled in providing support and oversight to Worldwide’s large national and global project and program management teams. She mentors staff and assesses program metrics to ensure quality, time, and budget deliverables are met. She has supported all research stages, including CMC, pharmacology, toxicology, regulatory, and clinical studies phase I-IV, and has worked on more than 10 multi-indication development programs. Her therapeutic experience in oncology includes solid tumors, ovarian cancer, hematological malignancies, acute myeloid leukemia (requiring stem cell transplant, peripheral, and cord blood), breast cancer, and glioblastoma.
An experienced team with an unbeatable network
Worldwide works with sponsors, leading subject matter experts, patients, and an experienced internal, executive-level team to give each and every oncology trial the right foundation for success and good decisions—no matter their stage of development.
Full-service solutions
Worldwide has a growing track record of successfully shepherding compounds from early-phase conceptualization through commercialization. And for those in need of study rescue, leading-edge study design consultation, or a fresh approach? We do that, too.
Site relationships that make a difference
Taking a unique approach to site feasibility and selection, Worldwide’s dedicated team of medical monitors and global project leads are directly involved in communication and relationship-building with sites. This results in rock-solid services and an irreplaceable “in-the-trenches” understanding of therapies, the competitive landscape, and the patient journey.
Patient-friendly recruitment tactics
Worldwide makes patient-centered logistics a key focus of all oncology trials, finding the right patients by partnering with indication-specific recruitment experts and successfully equipping research centers to reach patients beyond academic hubs.
Expertise You Can Rely On
We’ve cultivated a tenured, talented team of experts to craft unique, resourceful solutions for each and every project. Forge a partnership that matters and let Worldwide Clinical Trials Oncology introduce you to the research experience you deserve.
Oncology Experience
- Common Cancers
- Advanced Solid Tumors
- Breast Cancer
- Cervical Cancer
- Chemo Induced Anorexia or Cachexia
- Colorectal Cancer
- Endometrial Cancer
- Melanoma
- Myelodysplastic Syndrome
- Non-Hodgkin Lymphoma
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Stomach Cancer
- Tenosynovial Giant Cell Tumor
- Rare Cancers
- Acute Myeloid Leukemia (AML)
- B-Cell Non-Hodgkin Lymphoma
- Cutaneous T-Cell Lymphoma
- Gastrointestinal Stromal Tumor (GIST)
- Glioblastoma Multiforme (GBM)
- Hepatocellular Carcinoma
- Idiopathic Thrombocytopenic Purpura
- Triple-Negative Breast Cancer
- Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
